Although this methodological choice of study type is theoretically supported by the absence of a specific treatment suggested by guidelines, a very recent phase III trial which compared avelumab (a human anti-PD-L1 monoclonal antibody) to the physician's choice chemotherapy did not show improvements in OS or PFS in third-line of therapy of GC patients [16]. The gene discussed is CD274; the disease is gastric cancer.